Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|July 28, 2011
INC Research and Debiopharm Group Announce Strategic Partnership
Advertisement
INC Research
and
Debiopharm Group
(“Debiopharm”) announced a strategic partnership. Under the terms of the agreement, Debiopharm will entrust INC Research with the management of a clinical study linked to an important project in Debiopharm’s pipeline. Both parties have furthermore agreed on a framework partnership pertaining to future clinical studies to be conducted by INC Research for Debiopharm.
“Debiopharm’s reputation in establishing partnerships is aligned very closely with our vision of creating strategic relationships that improve the speed, efficiency, and quality of drug development,” said Kelvin Logan, PhD., president INC Research Europe and Asia Pacific. “We are pleased to offer our therapeutic expertise along with our experience in conducting trials globally to support Debiopharm’s drug development efforts in bringing innovative medicines to market more quickly and efficiently.”
INC Research's clinical delivery alliance structures can include complete management of a compound or therapeutic area; management of a specific function or set of critical processes; sharing in the risk and reward of a compound's performance; or acting as the sole source development partner for a customer. The company's proven experience with process-driven clinical research methods and its popular metrics-based Trusted Process® provides the foundation for successful strategic alliances.
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem
3
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
4
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
5